NGVT Stock Analysis: Ingevity | NYSE
Specialty Chemicals | NYSE, USA | Market Cap: 2.524m USD | 12M Return: 52.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 20.1M
EPS Trend: 15.7%
Qual. Beats: 1
Rev. Trend: -99.3%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Ingevity Corporation (NYSE: NGVT) is a U.S.-based specialty chemicals manufacturer headquartered in North Charleston, South Carolina. Founded in 1964 and spun off in 2016, the company operates three business segments: Performance Materials, which produces hardwood-based and chemically activated carbon products for automotive vapor emission control and purification applications; Performance Chemicals, which supplies additives and chemistries for pavement, road marking, agrochemical, and industrial uses; and Advanced Polymer Technologies, which makes caprolactone-based specialty polymers for coatings, adhesives, bioplastics, and medical devices. Ingevity sells globally across North America, Asia Pacific, Europe, the Middle East, Africa, and South America, serving customers through direct sales representatives, third-party agents, and distributors.
As a mid-cap player in the GICS Specialty Chemicals sub-industry, Ingevity participates in a fragmented sector where companies typically compete through application-specific formulation expertise rather than commodity-scale production. Its reliance on hardwood-based activated carbon ties a portion of its business to forestry-derived feedstocks, while the performance chemicals segment exposes it to infrastructure-spending cycles driven by road construction and maintenance activity.
- EV transition pressures gasoline vapor carbon demand
- US infrastructure spending lifts road technologies revenue
- Pine chemical feedstock costs squeeze specialty chemicals margins
| Net Income: -127.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 10.27 > 1.0 |
| NWC/Revenue: 14.23% < 20% (prev 19.65%; Δ -5.42% < -1%) |
| CFO/TA 0.18 > 3% & CFO 303.8m > Net Income -127.8m |
| Net Debt (1.19b) to EBITDA (17.1m): 69.57 < 3 |
| Current Ratio: 1.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (36.0m) vs 12m ago -1.81% < -2% |
| Gross Margin: 39.30% > 18% (prev 34.69%; Δ 4.61% > 0.5%) |
| Asset Turnover: 65.36% > 50% (prev 65.67%; Δ -0.31% > 0%) |
| Interest Coverage Ratio: -1.16 > 6 (EBIT TTM -84.6m / Interest Expense TTM 72.8m) |
| A: 0.10 (Total Current Assets 581.8m - Total Current Liabilities 409.4m) / Total Assets 1.65b |
| B: 0.28 (Retained Earnings 464.7m / Total Assets 1.65b) |
| C: -0.05 (EBIT TTM -84.6m / Avg Total Assets 1.85b) |
| D: 0.02 (Book Value of Equity 38.9m / Total Liabilities 1.61b) |
| Altman-Z'' = 1.32 = BB |
| DSRI: 1.03 (Receivables 151.2m/163.7m, Revenue 1.21b/1.35b) |
| GMI: 0.88 (GM 34.69% / 39.30%) |
| AQI: 0.65 (AQ_t 0.26 / AQ_t-1 0.40) |
| SGI: 0.90 (Revenue 1.21b / 1.35b) |
| TATA: -0.26 (NI -127.8m - CFO 303.8m) / TA 1.65b) |
| Beneish M = -3.42 (Cap -4..+1) = AA |
As of July 09, 2026, the stock is trading at USD 71.53 with a total of 262,661 shares traded. Over the past week, the price has changed by -4.21%, over one month by +6.87%, over three months by -2.55% and over the past year by +52.87%.
Current recommended Stop Loss: 67.10 (which is 6.2% or 1.9 ATR below the current price).
Ingevity has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy NGVT.
- StrongBuy: 1
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 85.5 | 19.5% |
P/E Forward = 9.9701
P/S = 2.1429
P/B = 64.8774
P/EG = 2.411
Revenue TTM = 1.21b USD
EBIT TTM = -84.6m USD
EBITDA TTM = 17.1m USD
Long Term Debt = 1.08b USD (from longTermDebt, last quarter)
Short Term Debt = 135.2m USD (from shortTermDebt, last quarter)
Debt = 1.29b USD (from shortLongTermDebtTotal, last quarter) + Leases 40.4m
Net Debt = 1.19b USD (calculated: Debt 1.29b - CCE 95.4m)
Enterprise Value = 3.71b USD (2.52b + Debt 1.29b - CCE 95.4m)
Interest Coverage Ratio = -1.16 (Ebit TTM -84.6m / Interest Expense TTM 72.8m)
EV/FCF = 15.11x (Enterprise Value 3.71b / FCF TTM 245.8m)
FCF Yield = 6.62% (FCF TTM 245.8m / Enterprise Value 3.71b)
FCF Margin = 20.29% (FCF TTM 245.8m / Revenue TTM 1.21b)
Net Margin = -10.55% (Net Income TTM -127.8m / Revenue TTM 1.21b)
Gross Margin = 39.30% ((Revenue TTM 1.21b - Cost of Revenue TTM 735.3m) / Revenue TTM)
Gross Margin QoQ = 45.12% (prev 34.42%)
Tobins Q-Ratio = 2.25 (Enterprise Value 3.71b / Total Assets 1.65b)
Interest Expense / Debt = 5.66% (Interest Expense 72.8m / Debt 1.29b)
Taxrate = 22.52% (6.80m / 30.2m)
NOPAT = -65.6m (EBIT -84.6m * (1 - 22.52%)) [loss with tax shield]
Current Ratio = 1.42 (Total Current Assets 581.8m / Total Current Liabilities 409.4m)
Debt / Equity = 33.04 (Debt 1.29b / totalStockholderEquity, last quarter 38.9m)
Debt / EBITDA = 69.57 (Net Debt 1.19b / EBITDA 17.1m)
Debt / FCF = 4.84 (Net Debt 1.19b / FCF TTM 245.8m)
Total Stockholder Equity = 81.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -6.90% (Net Income -127.8m / Total Assets 1.65b)
RoE = -156.1% (Net Income TTM -127.8m / Total Stockholder Equity 81.8m)
RoCE = -7.27% (EBIT -84.6m / Capital Employed (Equity 81.8m + L.T.Debt 1.08b))
RoIC = -4.98% (negative operating profit) (NOPAT -65.6m / Invested Capital 1.32b)
WACC = 8.94% (E(2.52b)/V(3.81b) * Re(11.25%) + D(1.29b)/V(3.81b) * Rd(5.66%) * (1-Tc(0.23)))
Discount Rate = 11.25% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 20.0 | Cagr: -0.25%
[DCF] Terminal Value 76.10% ; FCFF base≈185.5m ; Y1≈212.7m ; Y5≈313.0m
[DCF] Fair Price = 88.60 (EV 4.27b - Net Debt 1.19b = Equity 3.08b / Shares 34.8m; r=8.94% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 15.69 | EPS CAGR: 3.25% | SUE: 1.38 | # QB: 1
Revenue Correlation: -99.25 | Revenue CAGR: -13.48% | SUE: 0.12 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.35 | Chg30d=-2.59% | Revisions=-50% | Analysts=4
EPS next Quarter (2026-09-30): EPS=1.53 | Chg30d=+0.49% | Revisions=-50% | Analysts=4
EPS current Year (2026-12-31): EPS=4.93 | Chg30d=+0.00% | Revisions=-17% | GrowthEPS=+8.3% | GrowthRev=-14.8%
EPS next Year (2027-12-31): EPS=5.75 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+16.7% | GrowthRev=-2.1%
[Analyst] Revisions Ratio: -44% (up=3, down=10)